Annual Cash & Cash Equivalents
$11.46 B
-$1.93 B-14.44%
December 31, 2024
Summary
- As of February 7, 2025, NVS annual cash & cash equivalents is $11.46 billion, with the most recent change of -$1.93 billion (-14.44%) on December 31, 2024.
- During the last 3 years, NVS annual cash & cash equivalents has fallen by -$948.00 million (-7.64%).
- NVS annual cash & cash equivalents is now -14.44% below its all-time high of $13.39 billion, reached on December 31, 2023.
Performance
NVS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$11.46 B
-$2.15 B-15.80%
December 31, 2024
Summary
- As of February 7, 2025, NVS quarterly cash and cash equivalents is $11.46 billion, with the most recent change of -$2.15 billion (-15.80%) on December 31, 2024.
- Over the past year, NVS quarterly cash and cash equivalents has dropped by -$1.93 billion (-14.44%).
- NVS quarterly cash and cash equivalents is now -29.26% below its all-time high of $16.20 billion, reached on June 30, 2008.
Performance
NVS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.4% | -14.4% |
| 3 y3 years | -7.6% | -7.6% |
| 5 y5 years | +3.1% | -7.6% |
NVS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -14.4% | +52.4% | -17.3% | +216.1% |
| 5 y | 5-year | -14.4% | +52.4% | -17.3% | +216.1% |
| alltime | all time | -14.4% | +462.3% | -29.3% | +462.3% |
Novartis AG Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $11.46 B(-14.4%) | $11.46 B(-15.8%) |
| Sep 2024 | - | $13.61 B(+72.2%) |
| Jun 2024 | - | $7.90 B(-16.5%) |
| Mar 2024 | - | $9.47 B(-29.3%) |
| Dec 2023 | $13.39 B(+78.2%) | $13.39 B(+8.0%) |
| Sep 2023 | - | $12.40 B(+14.0%) |
| Jun 2023 | - | $10.88 B(-9.3%) |
| Mar 2023 | - | $12.00 B(+59.6%) |
| Dec 2022 | $7.52 B(-39.4%) | $7.52 B(-13.9%) |
| Sep 2022 | - | $8.73 B(+140.7%) |
| Jun 2022 | - | $3.63 B(-73.8%) |
| Mar 2022 | - | $13.85 B(+11.6%) |
| Dec 2021 | $12.41 B(+28.5%) | $12.41 B(+72.1%) |
| Sep 2021 | - | $7.21 B(+40.9%) |
| Jun 2021 | - | $5.12 B(+34.6%) |
| Mar 2021 | - | $3.80 B(-60.6%) |
| Dec 2020 | $9.66 B(-13.1%) | $9.66 B(+7.4%) |
| Sep 2020 | - | $8.99 B(+52.0%) |
| Jun 2020 | - | $5.92 B(+30.7%) |
| Mar 2020 | - | $4.53 B(-59.3%) |
| Dec 2019 | $11.11 B(-16.3%) | $11.11 B(+32.6%) |
| Sep 2019 | - | $8.38 B(-16.1%) |
| Jun 2019 | - | $9.99 B(+46.8%) |
| Mar 2019 | - | $6.81 B(-48.7%) |
| Dec 2018 | $13.27 B(+49.8%) | $13.27 B(-5.2%) |
| Sep 2018 | - | $14.00 B(+12.5%) |
| Jun 2018 | - | $12.45 B(+114.1%) |
| Mar 2018 | - | $5.81 B(-34.4%) |
| Dec 2017 | $8.86 B(+26.4%) | $8.86 B(+26.4%) |
| Dec 2016 | $7.01 B(+49.9%) | $7.01 B(+49.9%) |
| Dec 2015 | $4.67 B(-64.1%) | $4.67 B(-64.1%) |
| Dec 2014 | $13.02 B(+94.8%) | $13.02 B(+94.8%) |
| Dec 2013 | $6.69 B(+20.4%) | $6.69 B(+20.4%) |
| Dec 2012 | $5.55 B(+49.7%) | $5.55 B(+49.7%) |
| Dec 2011 | $3.71 B(-30.3%) | $3.71 B(-30.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $5.32 B(+83.8%) | $5.32 B(+83.8%) |
| Dec 2009 | $2.89 B(+42.0%) | $2.89 B(+42.0%) |
| Dec 2008 | $2.04 B(-62.0%) | $2.04 B(-75.0%) |
| Sep 2008 | - | $8.14 B(-49.8%) |
| Jun 2008 | - | $16.20 B(+49.3%) |
| Mar 2008 | - | $10.85 B(+102.4%) |
| Dec 2007 | $5.36 B(+40.5%) | $5.36 B(-63.1%) |
| Sep 2007 | - | $14.53 B(+92.5%) |
| Jun 2007 | - | $7.55 B(+8.5%) |
| Mar 2007 | - | $6.96 B(+82.4%) |
| Dec 2006 | $3.81 B(-39.6%) | $3.81 B(-55.3%) |
| Sep 2006 | - | $8.53 B(+16.7%) |
| Jun 2006 | - | $7.31 B(-34.2%) |
| Mar 2006 | - | $11.12 B(+75.9%) |
| Dec 2005 | $6.32 B(+3.9%) | $6.32 B(-20.5%) |
| Sep 2005 | - | $7.95 B(-15.8%) |
| Jun 2005 | - | $9.44 B(-23.1%) |
| Mar 2005 | - | $12.28 B(+101.9%) |
| Dec 2004 | $6.08 B(+7.7%) | $6.08 B(+91.3%) |
| Sep 2004 | - | $3.18 B(-10.9%) |
| Jun 2004 | - | $3.57 B(+9.9%) |
| Mar 2004 | - | $3.25 B(-42.5%) |
| Dec 2003 | $5.65 B(-2.6%) | $5.65 B(+20.5%) |
| Sep 2003 | - | $4.68 B(+2.9%) |
| Jun 2003 | - | $4.55 B(-23.8%) |
| Mar 2003 | - | $5.97 B(+3.0%) |
| Dec 2002 | $5.80 B(-13.8%) | $5.80 B(-43.9%) |
| Sep 2002 | - | $10.33 B(-19.9%) |
| Jun 2002 | - | $12.90 B(+91.8%) |
| Dec 2001 | $6.73 B(+23.3%) | $6.73 B(+155.0%) |
| Jun 2001 | - | $2.64 B(-51.6%) |
| Dec 2000 | $5.45 B(+38.3%) | $5.45 B(+59.5%) |
| Jun 2000 | - | $3.42 B |
| Dec 1999 | $3.94 B(-18.4%) | - |
| Dec 1998 | $4.83 B | - |
FAQ
- What is Novartis AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novartis AG?
- What is Novartis AG annual cash & cash equivalents year-on-year change?
- What is Novartis AG quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Novartis AG?
- What is Novartis AG quarterly cash and cash equivalents year-on-year change?
What is Novartis AG annual cash & cash equivalents?
The current annual cash & cash equivalents of NVS is $11.46 B
What is the all time high annual cash & cash equivalents for Novartis AG?
Novartis AG all-time high annual cash & cash equivalents is $13.39 B
What is Novartis AG annual cash & cash equivalents year-on-year change?
Over the past year, NVS annual cash & cash equivalents has changed by -$1.93 B (-14.44%)
What is Novartis AG quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVS is $11.46 B
What is the all time high quarterly cash and cash equivalents for Novartis AG?
Novartis AG all-time high quarterly cash and cash equivalents is $16.20 B
What is Novartis AG quarterly cash and cash equivalents year-on-year change?
Over the past year, NVS quarterly cash and cash equivalents has changed by -$1.93 B (-14.44%)